AI Proteins
- Company typePrivate
- Founded2022
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
AI Proteins firmographics
Firmographics- Name
- AI Proteins
- Legal name
- AI Proteins, Inc.
- Website
- https://aiproteins.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
AI Proteins industry classification
Industry- Product category
- Therapeutic Protein Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)
- akta.pro secondary industries
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where AI Proteins is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
AI Proteins business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Research collaboration payments: Upfront cash payments for research collaborations where AI Proteins discovers and optimizes miniproteins against targets of interest to partners
- Milestone payments: Potential development, regulatory, and commercial milestone payments from partners (e.g., up to $400M from Bristol Myers Squibb)
- Royalties on net sales: Royalties on net sales from successful commercialization of partnered miniprotein therapeutics
- Hub-and-spoke subsidiary model: Individual programs spun out into focused subsidiaries, enabling investors and partners to capture value from each new asset while the discovery engine keeps advancing
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
AI Proteins product offering
Product offeringCore offering
AI Proteins operates an AI-driven high-throughput platform for the de novo design and engineering of miniprotein therapeutics. The platform uses a closed-loop engine combining generative AI, synthetic biology, and robotics to create entirely synthetic proteins from first principles, unconstrained by evolution, with complete control over function, stability, and pharmacology. The company monetizes these capabilities through research collaborations and licensing agreements with pharmaceutical partners while advancing an internal pipeline of miniprotein candidates in oncology, inflammation, and metabolic disease.
Product overview
AI Proteins operates as a unified platform company built around its de novo miniprotein design technology. The core offering is an AI-driven high-throughput platform for designing synthetic proteins from scratch, which feeds into multiple therapeutic programs. The company maintains an internal pipeline including the TNFR1 program (Immunology & Inflammation), GLP-1 agonist program (Metabolic Diseases), and multiple oncology programs (Targeted Radiotherapy). Additionally, the company has partnered programs through collaborations with Bristol Myers Squibb (up to $400M value) and Vivtex (oral biologic therapies). The platform supports over 150 targets explored with multiple in vivo proofs-of-concept achieved.
Differentiator
Problem solved
Functional benefit
Products and services
- De Novo Miniprotein Design Platform A high-throughput AI-driven platform for designing entirely synthetic proteins from scratch (de novo), providing control over protein function, stability, and pharmacology. Uses a closed-loop engine combining generative AI design, automated synthesis, lab validation, and AI-directed optimization (AWES) to create miniproteins optimized for therapeutic applications. The platform is the core offering of AI Proteins and is licensed to partners through research collaboration and option agreements.
- TNFR1 Program Internal immunology and inflammation program developing a TNFR1 receptor antagonist miniprotein to inhibit TNFR1-mediated pro-inflammatory signaling for treating inflammatory diseases. Status: Discovery stage. The program has demonstrated equivalent efficacy to an approved antibody in an anti-inflammatory setting and is the subject of a strategic R&D collaboration with Vivtex Corporation to enable oral delivery.
- Oncology Pipeline (Targeted Radiotherapy) Multiple internal oncology programs developing de novo designed miniproteins as targeting agents for targeted radiotherapy, with tumor-killing validated in animal models for the immune activator program. Includes a collaborative research agreement with the University of Missouri to advance use of miniproteins labeled with alpha and beta-emitting radionuclides as cancer theranostics. Status: Discovery stage.
- GLP-1 Agonist Program Metabolic disease program developing GLP-1 receptor agonist miniproteins, which has demonstrated superior activity to semaglutide in vivo models. Status: Discovery stage.
- Bristol Myers Squibb Partnership Programs Partnered programs under the Bristol Myers Squibb research collaboration and option agreement (valued up to $400M). AI Proteins discovers and optimizes miniproteins against multiple undisclosed targets using its proprietary AI-driven platform, with Bristol Myers Squibb holding options for exclusive worldwide licenses.
Quantifiable outcome
- Miniprotein binders identified for more than 150 drug targets
- +5 more outcomes
Companies that use AI Proteins
Customer profileSegments2 records
Ideal customer profiles3 records
AI Proteins technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
AI Proteins partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and flagship.
- University of MissouricoreCollaborative Research Agreement with Dr. Carolyn Anderson's team to advance use of de novo designed miniproteins for targeted radioligand therapy (RLT). Joint effort to demonstrate effectiveness of miniproteins labeled with alpha and beta-emitting radionuclides as cancer theranostics.
- Bristol Myers SquibbflagshipResearch Collaboration and Option Agreement for discovery and development of novel miniprotein-based therapeutics. AI Proteins will discover and optimize miniproteins for two undisclosed targets using its proprietary AI-driven platform. Bristol Myers Squibb has option for exclusive worldwide license plus two additional target options. Deal valued up to $400M including upfront, expansion fees, milestones, and royalties.
- Vivtex CorporationcoreStrategic R&D collaboration to develop novel oral biologic therapies for inflammatory diseases. Partners leverage Vivtex's GI-ORIS Gut-on-chip and AI screening platform to evaluate and enhance oral bioavailability of AI Proteins' miniproteins targeting TNFR1. Companies jointly conduct and share costs, co-owning resulting data.
- Institute for Protein InnovationcoreFormer affiliation; founder Chris Bahl was a founding faculty member; company originated from technology developed at IPI
Scale indicators5 records
Recent moves9 records
Expansion highlights5 records
AI Proteins competitors and assessment
Company assessmentDirect peers
- Generate Biomedicines: Flagship Pioneering-backed company developing generative AI for de novo protein therapeutics. Most directly comparable to AI Proteins given shared focus on generative AI-driven protein design for therapeutic applications and similar hub-and-spoke subsidiary structure.
- Bicycle Therapeutics: Clinical-stage company developing bicyclic peptides (constrained peptides similar to miniproteins) for oncology with multiple partnered programs. Most directly comparable modality peer given shared focus on small, constrained, synthetic protein/peptide therapeutics with bicycle's BT7480 advancing to clinic. Philip Brandish joined AI Proteins from Bicycle.
- BigHat Biosciences: AI/ML-driven antibody design company using a closed-loop design-build-test-learn platform to engineer next-generation antibody therapeutics. Comparable in applying AI to de novo design of protein therapeutics with high-throughput experimental validation.
- AbCellera: Public AI-driven antibody discovery company with a tech platform partnership business model. Comparable in using AI/ML for therapeutic protein discovery and in partnering with large pharma companies, though focused on antibodies rather than de novo miniproteins.
- Cradle Bio: AI-driven protein engineering company applying generative models to design novel proteins. Comparable in platform technology (AI for protein design), though more focused on industrial enzymes and sustainability applications than therapeutics.
Emerging players
- Profluent Bio: AI protein design company spun out of the same Berkeley ecosystem that produced protein language models like ESM. Comparable in using generative AI for protein engineering, though earlier stage and more focused on gene editing and biologics discovery tools.
- Cyrus Biotechnology: Computational protein design and engineering company with the Rosetta software suite background. Comparable in applying computational methods to protein engineering for therapeutic applications.
- Menten AI: AI-first protein design company using generative models to design therapeutic proteins, including de novo enzymes and binders. Comparable in being an early-stage AI protein design company targeting therapeutics.
- Anagenex: AI-driven drug discovery company combining DNA-encoded libraries with generative AI for small molecule and protein therapeutic discovery. Comparable as an AI-first early-stage drug discovery platform.
Broad incumbents
- Isomorphic Labs: Alphabet/DeepMind-backed company applying AlphaFold-derived AI to drug discovery. Comparable as an AI-driven protein/drug design company, though broader in scope (small molecules, biologics) and significantly better capitalized.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
AI Proteins social profiles
Digital presenceAI Proteins financial estimates
Financial estimateRevenue estimate
Valuation estimate
AI Proteins leadership team
Management profileNumber of profiles
Profiles14 records
AI Proteins funding detail
Funding detailFunding overview
Funding rounds8 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AI Proteins M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AI Proteins
What does AI Proteins do?
AI Proteins operates an AI-driven high-throughput platform for the de novo design and engineering of miniprotein therapeutics. The platform uses a closed-loop engine combining generative AI, synthetic biology, and robotics to create entirely synthetic proteins from first principles, unconstrained by evolution, with complete control over function, stability, and pharmacology. The company monetizes these capabilities through research collaborations and licensing agreements with pharmaceutical partners while advancing an internal pipeline of miniprotein candidates in oncology, inflammation, and metabolic disease.
Is AI Proteins a public or private company?
AI Proteins is a private company. It is classified as venture growth investor backed and is currently operating.
When was AI Proteins founded?
AI Proteins was founded in 2022. It employs 11 to 50 people.
Where is AI Proteins based?
AI Proteins is headquartered in Boston, United States, in the North America region.
How does AI Proteins make money?
Four revenue lines are on record. Research collaboration payments are the primary driver. The others are milestone payments, royalties on net sales and hub-and-spoke subsidiary model.
Who are AI Proteins's main competitors?
Direct peers on record are Generate Biomedicines, Bicycle Therapeutics, BigHat Biosciences, AbCellera and Cradle Bio. Emerging players are Profluent Bio, Cyrus Biotechnology, Menten AI and Anagenex. Isomorphic Labs is listed as a broad incumbent.
Does AI Proteins have an API?
No public API is recorded for AI Proteins.
What industry is AI Proteins in?
AI Proteins's product category is Therapeutic Protein Discovery. Its primary akta.pro industry code is HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2836.